Gut Molecule ImP Tied to Alzheimer's Brain Changes — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UW-Madison researchers identified imidazole propionate (ImP), a compound produced by gut bacteria from the amino acid histidine, as a potential driver of Alzheimer's-related brain changes in a study published in Nature Communications.
- In mouse experiments, ImP reaching the brain increased accumulation of beta amyloid and tau proteins — the two hallmark proteins of Alzheimer's — ultimately leading to neuron death.
- Blood analysis from nearly 1,200 participants in the Wisconsin Registry for Alzheimer's Prevention showed those with higher ImP levels carried more biological markers of dementia and experienced significantly faster cognitive decline over time.
- A genetic variation associated with higher bloodstream ImP levels was found in about 43% of study participants; the same variation had previously been tied to increased Alzheimer's risk in large-scale genetic studies.
- Researchers suspect the variation affects how efficiently the kidneys clear ImP from circulation, which could explain why some individuals accumulate substantially more of the compound.
- Collaborators from UCLA and the University of Gothenburg joined the UW-Madison team, who drew a statin analogy — suggesting a future drug that lowers ImP in the blood could function like statins do for cholesterol and heart disease.
- ImP had previously been linked to type 2 diabetes and coronary artery disease, indicating the molecule's harmful effects may extend across multiple organ systems beyond the brain.
Why it matters: Nearly 43% of study participants carry a genetic variation linked to higher ImP levels, identifying a large at-risk group that a statin-style ImP-lowering drug — the treatment parallel researchers Bendlin and Rey draw — would be specifically designed to treat.
Ask SkimNews
